🇺🇸 FDA
Patent

US 8263651

Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors

granted A61KA61K31/17A61K31/192

Quick answer

US patent 8263651 (Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors) held by The Regents of the University of California expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/17, A61K31/192, A61K31/202, A61K31/335